Diagnostic firm Banyan Biomarkers reported successful clinical trial results for its test to identify traumatic brain injury (TBI). The use of Banyan’s technology could reduce the use of computed tomography (CT) scans, the San Diego-based company said.

The two biomarkers in Banyan Biomarkers’ blood test are ubiquitin c-terminal hydrolase-L 1 (UCH-L1) and glial fibrillary acidic protein (GFAP), both of which are detectable in blood shortly after a traumatic brain injury (TBI).

The test positively identified all of the trial subjects who ended up with a positive CT scan. Early biomarker testing for patients with mild to moderate TBI could decrease the patient’s health care costs and the risk for developing cancer.

"This study is an important step in developing an objective test for the evaluation of TBI patients,” lead author Dr. Robert Welch, professor of emergency medicine at Wayne State University said in a press release. "An objective blood test for TBI has the potential to improve evaluation and clinical outcomes for millions of people that suffer a head injury each year.”

The study included 251 patients with mild to moderate TBI who presented to seven emergency departments in the U.S. and Europe. All patients underwent a CT scan and had blood drawn for the biomarker analysis within six hours of injury.

The results of the study, supported by the U.S. Army Medical Research and Materiel Command, were published online in the Journal of Neurotrauma on Oct. 15. A larger study with 2,000 subjects will be released next year.